News for Protara Therapeutics, Inc. (TARA)

Published at

Jun 2, 2025 11:46 PM

by gurufocus.com

negative

negative

Protara Therapeutics (TARA) Appoints New Chief Commercial Officer | TARA Stock News

Protara Therapeutics (TARA) has announced that William "Bill" Conkling has joined the company as Chief Commercial Officer. Conkling brings with him over 20 year

TARA

Read more →
Published at

Jun 2, 2025 11:17 PM

by gurufocus.com

negative

negative

Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer | TARA Stock News

Protara Therapeutics (TARA) has appointed William "Bill" Conkling as Chief Commercial Officer. Conkling brings over 20 years of experience in commercializin

TARA

Read more →
Published at

May 28, 2025 12:42 PM

by seekingalpha.com

mixed

mixed

Wall Street Breakfast Podcast: Shein Aims For Hong Kong IPO

Shein turns to Hong Kong for listing amid London IPO hurdles - report. Travel stocks buoyed by EU tariff pause. Compass Diversified stock craters after takes steps to enhance liquidity.

ZNTL TRIP TARA RCL EXPE CCL BOX ABNB AAPL PFGC COMP CODI BLDE COWNL COWN

Read more →
Published at

May 22, 2025 6:32 PM

by gurufocus.com

neutral

neutral

Protara Therapeutics (TARA) Initiates Coverage with a Buy Rating | TARA Stock News

On May 22, 2025, Jones Trading initiated coverage on Protara Therapeutics (TARA) with a "Buy" rating. This coverage comes with an announced price target of $21.

TARA

Read more →
Published at

May 22, 2025 2:45 PM

by gurufocus.com

neutral

neutral

Protara Therapeutics (TARA) Receives Buy Rating with $21 Price Target | TARA Stock News

JonesResearch analyst Soumit Roy has begun coverage of Protara Therapeutics (TARA) with a Buy recommendation, setting a price target of $21. Currently, the stoc

TARA

Read more →
Published at

May 17, 2025 11:15 AM

by gurufocus.com

positive

positive

Insider Buying: Richard Levy Acquires 20,000 Shares of Protara Therapeutics Inc (TARA)

On May 14, 2025, Richard Levy, a Director at Protara Therapeutics Inc (TARA), purchased 20,000 shares of the company. Following this transaction, the insider no

TARA

Read more →
Published at

May 2, 2025 12:00 AM

by gurufocus.com

negative

negative

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. ( TARA) (”Protara” or the ”Company”), a clinical-stage company developing transf

TARA

Read more →
Published at

Apr 28, 2025 6:38 PM

by benzinga.com

mixed

mixed

Crude Oil Down 2%; Roper Technologies Increases 2025 Outlook - CG Oncology (NASDAQ:CGON), Galmed Pharmaceuticals (NASDAQ:GLMD)

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 200 points on Monday. The Dow traded down 0.27% to 40,004.11 while th...

SPRB PLUN.DE PLUG.MX PLUG GRPN.MX GRPN 0R1H.L ROP.MX ROP GLMD 0KXM.L TARA

Read more →
Published at

Apr 28, 2025 3:56 PM

by benzinga.com

mixed

mixed

Dow Jumps Over 150 Points; Domino's Pizza Posts Upbeat Earnings - CG Oncology (NASDAQ:CGON), Domino's Pizza (NASDAQ:DPZ)

U.S. stocks traded higher this morning, with the Dow Jones index more than 150 points on Monday. Following the market opening Monday, the Dow traded up 0.47% t...

SPRB GLMD TARA

Read more →
Published at

Apr 26, 2025 5:00 PM

by gurufocus.com

mixed

mixed

Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC

TARA-002 demonstrates 100% complete response rate at any time and 67% 12-month landmark complete response rate in BCG-Unresponsive patientsTARA-002 demonstrates

CHGCY CHGCF 4519.T TARA

Read more →
Published at

Apr 26, 2025 4:10 PM

by manilatimes.net

mixed

mixed

Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC

**media[606500]**

CHGCY CHGCF 4519.T TARA

Read more →
Published at

Apr 23, 2025 4:00 PM

by gurufocus.com

mixed

mixed

Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025

NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. ( TARA), a clinical-stage company developing transformative therapies for the treatmen

CHGCY CHGCF 4519.T TARA

Read more →
Published at

Apr 16, 2025 3:27 PM

by benzinga.com

positive

positive

This UroGen Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Korro Bio (NASDAQ:KRRO), CG Oncology (NASDAQ:CGON)

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

URGN TARA PCTY 0XOD.L

Read more →
Published at

Apr 16, 2025 2:25 PM

by gurufocus.com

neutral

neutral

Protara Therapeutics (TARA) Rated Outperform with $12 Target by Scotiabank | TARA Stock News

Scotiabank analyst George Farmer has initiated coverage on Protara Therapeutics (TARA), giving it an Outperform rating and setting a price target of $12. The co

TARA

Read more →
Published at

Apr 16, 2025 12:00 AM

by gurufocus.com

mixed

mixed

Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer

NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.( TARA), a clinical-stage company developing transformative therapies for the treatment

SGEN AZN TARA

Read more →
Published at

Apr 15, 2025 11:45 PM

by gurufocus.com

neutral

neutral

Protara Therapeutics (TARA) Names Leonardo Viana Nicacio as New Chief Medical Officer | TARA Stock News

Protara Therapeutics (TARA) has appointed Leonardo Viana Nicacio as its new Chief Medical Officer. Nicacio joins the company with nearly two decades of extensiv

TARA

Read more →
Published at

Apr 15, 2025 10:29 PM

by manilatimes.net

mixed

mixed

Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer

**media[596099]**

SGEN AZN TARA

Read more →
Published at

Apr 11, 2025 12:00 AM

by gurufocus.com

mixed

mixed

Protara Therapeutics to Present Interim Analysis from the Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the American Urological Association Annual Meeting

NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.( TARA), a clinical-stage company developing transformative therapies for the treatment

CHGCY CHGCF 4519.T TARA

Read more →
Published at

Apr 10, 2025 10:11 PM

by manilatimes.net

mixed

mixed

Protara Therapeutics to Present Interim Analysis from the Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the American Urological Association Annual Meeting

**media[592008]**

CHGCY CHGCF 4519.T TARA

Read more →
Published at

Apr 9, 2025 6:00 PM

by zacks.com

neutral

neutral

Protara Therapeutics (TARA) Moves to Buy: Rationale Behind the Upgrade

Protara Therapeutics (TARA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

TARA

Read more →